Stockscreener 앱 받기
1.93
1.05%
0.02
전일 마감가:
$1.91
열려 있는:
$1.9247
하루 거래량:
33,522
Relative Volume:
0.15
시가총액:
$12.94M
수익:
$2.35M
순이익/손실:
$-2.56M
주가수익비율:
-4.3071
EPS:
-0.4481
순현금흐름:
-
1주 성능:
+3.88%
1개월 성능:
+12.87%
6개월 성능:
+5.41%
1년 성능:
-28.16%
1일 변동 폭
$1.875
$1.94
1주일 범위
$1.80
$1.94
52주 변동 폭
$1.50
$2.867
이뮤론 Stock (IMRN) Company Profile
IMRN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMRN
Immuron Limited Adr
|
1.93 | 12.87M | 2.35M | -2.56M | 0 | -0.4481 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
이뮤론 주식(IMRN)의 최신 뉴스
Is it too late to sell Immuron Limited Depositary ReceiptMarket Activity Report & Fast Moving Trade Plans - Newser
Does Immuron Limited Depositary Receipt fit your quant trading modelJuly 2025 Price Swings & High Win Rate Trade Tips - Newser
Statistical indicators supporting Immuron Limited Depositary Receipt’s strengthPortfolio Risk Summary & Real-Time Sentiment Analysis - Newser
What institutional flow reveals about Immuron Limited Depositary ReceiptEarnings Growth Summary & Entry Point Strategy Guides - Newser
Immuron partners with InvestorHub - GlobeNewswire Inc.
Immuron Limited Depositary Receipt stock trend forecastWeekly Investment Summary & AI Optimized Trading Strategy Guides - Newser
Visualizing Immuron Limited Depositary Receipt stock with heatmapsAI Trading Forecast Based on Big Data - Newser
BNY Mellon Increases Stake in Immuron Limited - TipRanks
Immuron Limited Announces Cessation of Securities - TipRanks
What drives Immuron Limited Depositary Receipt stock priceHigh-yield capital appreciation - jammulinksnews.com
Immuron - GlobeNewswire Inc.
Immuron Crushes Sales Forecast: North America Soars 76%, Global Revenue Breaks Records at $7.3M - Stock Titan
immuron ltd files for quotation of securities on ASX By Investing.com - Investing.com South Africa
immuron ltd files for quotation of securities on ASX - Investing.com
IMRNImmuron Ltd Latest Stock News & Market Updates - Stock Titan
Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS) - BioSpace
Immuron: Targeted oral antibodies to treat infectious diseases - Innovation News Network
Immuron: US FDA provides favourable feedback ahead of investigational new drug application for IMM-529 - Proactive financial news
Immuron Plans Phase 2 Trial for IMM-529 following FDA review - GlobeNewswire
Immuron requests pre-IND meeting for IMM-529 with FDA filing - GlobeNewswire
Why PriceSmart Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket - Markets Insider
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.34% - Investing.com UK
The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates - Yahoo Finance
IMC Reports Rising Revenues & Eyes Colitis Market - Next Investors
IMC Stock Price and Chart — ASX:IMC - TradingView
이뮤론 (IMRN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.93%
0.10%
자본화:
|
볼륨(24시간):